for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Gilead Sciences, Inc.

GILD.O

Latest Trade

63.15USD

Change

-0.79(-1.24%)

Volume

18,685,066

Today's Range

62.84

 - 

64.20

52 Week Range

60.89

 - 

70.50

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
63.94
Open
64.07
Volume
18,685,066
3M AVG Volume
143.87
Today's High
64.20
Today's Low
62.84
52 Week High
70.50
52 Week Low
60.89
Shares Out (MIL)
1,265.15
Market Cap (MIL)
80,893.41
Forward P/E
--
Dividend (Yield %)
3.94

Next Event

Q4 2019 Gilead Sciences Inc Earnings Release

Latest Developments

More

Kyverna Therapeutics Secures $25 Mln Series A Funding From Key Investors And Enters Into Strategic Collaboration With Gilead Sciences

Xencor And Gilead Enter License Agreement For Use Of Xmab Antibody Technologies In Investigational Agents For HIV

Gilead And Eisai Enter Into Agreement In Japan For Co-Promotion Of The Filgotinib

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Contact Info

333 LAKESIDE DR

+1.650.5743000

https://www.gilead.com/

Executive Leadership

Daniel O'Day

Chairman of the Board, Chief Executive Officer

Andrew D. Dickinson

Chief Financial Officer

Brett Alan Pletcher

Executive Vice President, Chief Compliance Officer, General Counsel

Jyoti Mehra

Executive Vice President of Human Resources

Johanna Mercier

Chief Commercial Officer

Key Stats

2.29 mean rating - 28 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

30.4K

2017

26.1K

2018

22.1K

2019(E)

22.3K
EPS (USD)

2016

11.570

2017

8.840

2018

6.670

2019(E)

7.009
Price To Earnings (TTM)
30.37
Price To Sales (TTM)
3.62
Price To Book (MRQ)
3.93
Price To Cash Flow (TTM)
19.71
Total Debt To Equity (MRQ)
119.34
LT Debt To Equity (MRQ)
107.21
Return on Investment (TTM)
5.20
Return on Equity (TTM)
4.36

Latest News

Latest News

Gilead assessing potential use of Ebola drug as China virus treatment

Gilead Sciences Inc said on Thursday it was assessing whether its experimental Ebola treatment could be used against the new coronavirus that has sickened hundreds of people in China and led to at least 18 deaths.

Gilead assessing Ebola drug as possible coronavirus treatment

Gilead Sciences Inc said on Thursday it was assessing whether its experimental Ebola treatment could be used to treat coronavirus infection.

Gilead's NASH combination treatment fails mid-stage study

Gilead Sciences Inc said on Monday all combinations of its three drugs to treat NASH were unsuccessful in a mid-stage study, the latest failure in a string of trials seeking to develop the first approved treatment for the fatty liver disease.

Gilead's NASH combination treatment fails main goal of mid-stage study

Gilead Sciences Inc said on Monday all combinations of its three drugs to treat non-alcoholic steatohepatitis (NASH)failed to meet the main goal of a mid-stage study, the latest in a string of failures to treat the fatty liver disease that has no approved treatment.

Bristol-Myers wins $752 million in U.S. patent case against Gilead

Bristol-Myers Squibb Co on Friday said it won a $752 million jury verdict against Gilead Sciences Inc in a U.S. patent dispute relating to technology for treating cancer.

Bristol-Myers prevails over Gilead in Yescarta royalty row - Bloomberg Law

Bristol-Myers Squibb Co won a patent infringement trial against Gilead Sciences Inc's unit Kite Pharma over cancer immunotherapy Yescarta, Bloomberg Law reported on Friday.

Half of lymphoma patients alive three years after Gilead cell therapy treatment: study

Nearly half of lymphoma patients treated with Gilead Sciences Inc's Yescarta were alive at least three years after a one-time infusion of the CAR-T cell therapy, according to data presented on Saturday.

Merck loses bid to revive $2.54 billion patent verdict against Gilead

A U.S. appeals court on Wednesday dealt a major blow to Merck & Co Inc <MRK.N> as it upheld a ruling that threw out a $2.54 billion jury verdict the drugmaker had won against Gilead Sciences Inc <GILD.O>.

Merck loses bid to revive $2.54 billion patent verdict against Gilead

A U.S. appeals court on Wednesday dealt a major blow to Merck & Co Inc as it upheld a ruling that threw out a $2.54 billion jury verdict the drugmaker had won against Gilead Sciences Inc.

Gilead third-quarter results in line, but Yescarta sales dip

Gilead Sciences Inc <GILD.O> on Thursday posted third-quarter results largely in line with Wall Street estimates, led by higher HIV drug sales, but sales of cancer cell therapy Yescarta fell slightly from the previous quarter.

Gilead posts third-quarter net loss, sales in line with Street estimates

Gilead Sciences Inc on Thursday reported third-quarter results largely in line with Wall Street estimates, led by higher sales of its HIV drugs, but deal-related costs led to a net loss.

BRIEF-Gilead Sciences Appoints Merdad Parsey As Chief Medical Officer

* GILEAD SCIENCES APPOINTS MERDAD PARSEY, MD, PHD AS CHIEF MEDICAL OFFICER

U.S. FDA approves Gilead's Descovy for HIV prevention

The U.S. Food and Drug Administration on Thursday approved Gilead Sciences Inc's <GILD.O> Descovy to reduce the risk of sexually acquired HIV infection in men and transgender women who have sex with men.

U.S. FDA approves Gilead's HIV prevention treatment

The U.S. Food and Drug Administration on Thursday approved Gilead Sciences Inc's drug, Descovy, to reduce the risk of sexually acquired HIV infection.

FDA flags risks from AbbVie, Gilead, Merck hepatitis C drugs to certain patients

The U.S. Food and Drug Administration said on Wednesday it had identified 63 cases of worsening liver function in certain patients taking hepatitis C medicines made by drugmakers Merck & Co Inc, Gilead Sciences and AbbVie Inc.

FDA flags serious risks with hepatitis C drugs from AbbVie, Gilead and Merck

The U.S. Food and Drug Administration said on Wednesday it had identified 63 cases of worsening liver function in certain patients taking hepatitis C medicines made by drugmakers Merck & Co Inc, Gilead Sciences and AbbVie Inc.

GSK's long acting HIV injection gets boost from study

GlaxoSmithKline's experimental HIV injection is as effective when given every other month as monthly, according to a study, a convenience that could help the British drugmaker in its battle against a rival drug from Gilead Sciences.GSK's two-drug injection was as effective...

Medicare to cover expensive cancer cell therapies

The U.S. Centers for Medicare and Medicaid Services (CMS) on Wednesday said it has finalized a decision to cover expensive cancer cell therapies sold by Gilead Sciences Inc <GILD.O> and Novartis AG <NOVN.S>.

Patient groups push back against Gilead's pricey HIV prevention treatment

Gilead Sciences Inc <GILD.O> hopes to soon introduce a pricey new pill to prevent HIV in people at risk of contracting the infection, but the drugmaker faces opposition from an unusual source: patient advocates.

FDA panel backs Gilead's HIV prevention drug Descovy, except in women

An FDA advisory panel on Wednesday voted in favor of Gilead Sciences Inc's combination drug to reduce the risk of sexually acquired HIV infection in men and transgender women who have sex with men.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up